Statins and sepsis: Good bullet, disappearing target

Journal of the American Osteopathic Association

Volumn 108, Issue 9, 2008, Pages 486-490

  Woerndle, Richard H ^a   Maxwell, Daniel L ^b  

^a Southeastern Regional Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPROSTACYCLIN; BRADYKININ ANTAGONIST; CD18 ANTIGEN; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN ANTIBODY; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTACYCLIN DERIVATIVE; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; ATHEROSCLEROSIS; CAUSE OF DEATH; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG TARGETING; DRUG USE; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PRESCRIPTION; REVIEW; SEPSIS;

BACTEREMIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 52249110006     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-1554.
3. Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D; CUB-Réa Study Group. Incidence and impact of organ dysfunctions associated with sepsis. Chest. 2005;127:942-951. Available at: http://www.chestjournal.org/cgi/ content/full/127/3/942. Accessed August 22, 2008.
4. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
5. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-1308.
6. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
7. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
8. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
9. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins [review]. Kidney Int. 2003;63:12-23.
10. Corona A, Raimondi F, Singer M. Statin use and mortality in the bacteremic critically ill patient. Crit Care Med. 2006;34:1270-1272.
11. Warnholtz A, Genth-Zotz S, Munzel T. Should treatment of sepsis include statins [editorial]? Circulation. 2005;111:1735-1737. Available at: http://circ.ahajournals.org/cgi/content/full/111/14/1735. Accessed August 22, 2008.
12. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis [published online ahead of print May 3, 2004]. Circulation. 2004;109:2560-2565. Available at: http://circ.ahajournals. org/cgi/content/full/109/21/2560. Accessed August 22, 2008.
13. Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock. 2004;21:271-275.
14. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413-418.
15. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis [published online ahead of print August 2, 2004]. Circulation. 2004;110:880-885. Available at: http://circ.ahajournals.org/cgi/content/full/110/7/880. Accessed August 22, 2008.
16. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia [published online ahead of print September 20, 2001]. Clin Infect Dis. 2001;33:1352-1357. Available at: http://www.journals.uchicago.edu/CID/journal/issues/v33n8/001561/001561.html. Accessed August 29, 2007.
17. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia [published online ahead of print November 10, 2005]. Intensive Care Med. 2006;32:75-79.
18. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker [published online ahead of print August 16, 2005]? Intensive Care Med. 2006;32:160-164.
19. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, Schønheyder HC, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34:1080-1086.
20. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
21. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305. Available at: http://atvb.ahajournals.org/cgi/content/full/22/2/300. Accessed August 22, 2008.
22. Inoue K, Takano H, Yanagisawa R, Sakurai M, Yoshikawa T. Statin, inflammation, and sepsis [letter]. Chest. 2004;125:2365. Available at: http://www.chest journal.org/cgi/content/full/125/6/2365. Accessed August 22, 2008.
23. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692.
24. Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, et al. Simvastatin prevents vascular hyporeactivity during inflammation [published online ahead of print November 1, 2004]. Circulation. 2004;110:3349-3354. Available at: http://circ.ahajournals.org/cgi/content/full/110/21/3349. Accessed August 22, 2008.
25. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol. 2002;40:611-617.
26. BandohT, Sato EF, Mitani H, Nakashima A, Hoshi K, Inoue M. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol Pharm Bull. 2003;26:818-822.
27. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69. Available at: http://atvb.ahajournals.org/cgi/content/full/20/1/61. Accessed August 22, 2008.
28. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock [review]. N Engl J Med. 2001;345:588-595.
29. Thomas L. Germs. N Engl J Med. 1972;287:553-555.
30. Warren HS. Strategies for the treatment of sepsis. N Engl J Med. 1997;336:952-953.
31. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med. 2001;29(7 suppl):S21-S27.
32. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24:163-172.
33. Bone RC. Why sepsis trials fail. JAMA. 1996;276:565-566.
34. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment [review]. Crit Care Med. 1997;25:1095-1100.
35. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Int Med 1994;120:771-783. Available at: http://www.annals.org/cgi/content/full/120/9/771. Accessed August 22, 2008.
36. Bernard GB, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336:912-918.
37. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991;324:429-436.
38. Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA. 1997;277:482-487.
39. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
40. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al; IL-1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22:12-21.
41. Sharar SR, Winn RK, Murry CE, Harlan JM, Rice CL. A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose Staphylococcus aureus injection in rabbits. Surgery. 1991;110:213-219.
42. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338:1557-1558.
43. Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med. 1994;22:1720-1728.
44. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334:1697-1720. Available at: http://content.nejm.org/cgi/content/full/334/ 26/1697. Accessed August 26, 2008.
45. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study [published correction appears in Crit Care Med. 1996;24:1608]. Crit Care Med. 1996;24:733-742.
46. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273:934-941.
47. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24:1125-1128.
48. Lederer JA, Rodrick ML, Mannick JA. The effects of injury on the adaptive immune response [review]. Shock. 1999;11:153-159.
49. O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg. 1995;222:482-492. Available at: http://www.pubmed central.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7574928. Accessed August 22, 2008.
50. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181:176-180. Available at: http://www.journals.uchicago.edu/JID/journal/issues/v181n1/ 990857/990857.html. Accessed August 29, 2007.
51. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27:1230-1251.
52. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997;390:350-351.
53. Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock [published online ahead of print March 17, 2004]. Am J Respir Crit Care Med. 2004;169:1144-1151. Available at: http://ajrccm.ats journals.org/cgi/content/full/169/10/1144. Accessed August 22, 2008.
54. Pangault C, Le Tulzo Y, Tattevin P, Guilloux V, Bescher N, Drénou B. Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit Care Med. 2006;34:1193-1201.
55. Fraunberger P, Pilz G, Cremer P, Werdan K, Walli AK. Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock. 1998;10:359-363.
56. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med. 1996;24:584-589.
57. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31:1359-1366.
58. Engelberg H. Low serum cholesterol and suicide. Lancet. 1992;339:727-729.
59. Fraunberger P, Nagel D, Walli AK, Seidel D. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med. 2000;28:3574-3575.
60. Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur Heart J. 1993;14(suppl K):125-129.
61. Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med. 1969;281:1081-1086.
62. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990;86:696-702. Available at: http://www. pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=2394827. Accessed August 22, 2008.
63. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, et al. Structure and function of lipopolysaccharide binding protein. Science. 1990;249:1429-1431.
64. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988;81:1925-1937. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedi d=3384955. Accessed August 22, 2008.
65. Netea MG, Demacker PN, Kullberg BJ, Jacobs LE, Verver-Jansen TJ, Boerman OC, et al. Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. Cytokine. 1998;10:766-772.
66. McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock. 2003;20:551-557.
67. Feingold KR, Grunfeld C. Lipoproteins: are they important components of host defense? Hepatology. 1997;26:1685-1686.